Cynosure Receives Expanded FDA Clearance to Market PicoSure for Treatment of Acne Scars

Cynosure has received FDA 510(k) clearance to market its flagship PicoSureFOCUS picosecond laser work station for the treatment of acne scars.

The PicoSure FOCUS is the world’s first picosecond laser for skin revitalisation, toning and texture,wrinkles and fine lines, pigmented lesions and now acne scars.

“The clearance to treat acne scarring with PicoSure represents a significant milestone in our strategy to pursue expanded indications that demonstrate the breadth of this technology,” said Cynosure president and chief executive officer Michael Davin. “The treatment of acne scarring represents a large global market, and we believe that approval of PicoSure effectively positions us to capitalise on this opportunity. At the same time, we continue to pursue new FDA marketing clearances for PicoSure in additional indications such as the treatment of wrinkles. Our FOCUS lensarray microscopically concentrates laser energy on small treatment areasof tissue while stimulating collagen production and remodeling. With its unique pulse format, we believe FOCUS technology presents the opportunity for physicians to offer highly customisable treatments for their patients.”